Cryptocurrency investment firm Techemy Capital has announced the launch of its Holistic ETH-BTC portfolio in partnership with Enzyme Finance (formerly Melon Protocol).
The portfolio is powered by Brave New Coin, while it also uses Techemy’s long and short trading strategies to maximise exposure to Bitcoin and Ethereum price action.
It quantifies bullish or bearish conditions to add or subtract from each investor’s starting position, based on an assessment of on-chain activity, token age spent, and technical analysis.
The portfolio is powered by Enzyme, an Ethereum-based infrastructure for on-chain asset management. Enzyme connects fund managers to a pool of potential investors, making it easier to create a community.
Rotational assets in the portfolio include Wrapped Bitcoin (WBTC), Ethereum (ETH), USD Coin (USDC), Inverse ETH (iETH) and Inverse BTC (iBTC).
The inverse assets allow Techemy’s team of traders to effectively short either Bitcoin or Ethereum depending on market conditions.
Techemy is able to access deep liquidity across the entire Ethereum network thanks to Enzyme’s integration with Paraswap, a Decentralised Exchange aggregator that optimises order routing and minimises slippage.
“Following the exceptional performance of Techemy Capital’s private DeFi Portfolio in 2020, we are excited to open this product through Enzyme to the broader investor community,” said Fran Strajnar, Founder of Techemy Capital and Brave New Coin. “We are looking forward to working with Enzyme and our growing number of exchange partners to deliver the highest-grade digital asset and DeFi investment products.”
For more news, guides and cryptocurrency analysis, click here.
Las Vegas, US, 1st November 2024, Chainwire
From digital art to real-estate assets, NFTs have become a significant attraction for investors who…
Singapore, Singapore, 21st October 2024, Chainwire
HO CHI MINH, Vietnam, 17th October 2024, Chainwire
London, UK, 16th October 2024, Chainwire
Sinagpore, Singapore, 16th October 2024, Chainwire